ARIADAllison Research Index of Art and Design
ARIADAssociation pour la Recherche et l'Information sur l'Aide au Développement (French: Association for Research and Information on Development Aid)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc.
The SEC alleges that that Altvater traded in Ariad's stock in advance of announcements about Food and Drug Administration decisions that affected the sales and marketing of the company's main product, a drug to treat cancer.
"The acquisition of ARIAD is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders," said Christophe Weber, president and chief executive officer of Takeda.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is an orphan oncology company focused on transforming the lives of cancer patients with breakthrough medicines.
Mark Tanner, general manager of Ariad UK, said: "Our goal is to deliver innovative solutions that address gaps in care for patients who are left with few clinical treatment options.
Panelists include Devgan, Fran Young of Shire, Purvi Mody of Ariad Pharmaceuticals, Jennifer Almekinder of Merz, and Eric Crown of Abbvie.
CAMBRIDGE -- Ariad Pharmaceuticals has received approval to relaunch its leukemia drug Iclusig after addressing safety concerns raised by federal regulators in October.
BANKING AND CREDIT NEWS-January 25, 2013--JP Morgan, Cowen and Jefferies lead Ariad Pharma common stock offering(C)2013 M2 COMMUNICATIONS
Researchers will be working with American company ARIAD Pharmaceuticals, the UK National Cancer Research Institute and a number of other universities to help assess how to select the best treatment available for patients with the illness.
A first-in-human, dose-finding study in advanced tumors provided preliminary evidence that Ariad Pharmaceuticals' oral dual ALK-EGFR inhibitor AP26113 is active in ALK-positive as well as EGFR-mutant NSCLC.
These questions arose after the Court of Customs and Patent Appeals's 1967 decision in In re Ruschig regarding the written description doctrine, (81) if not earlier, and they were most recently the subject of the Federal Circuit's much anticipated en banc decision in Ariad Pharmaceuticals, Inc.
(22) The Federal Circuit reviewed its decision in Ariad v.